People  |   Processes   |   Predictions

 LIVE ONLINE 7 October 2021

Advanced Therapies Integrates Media Centre 2021

We are delighted to have the support of our lead media partners, The Cell & Gene Curator and The Medicine Maker.

We will be working with them to ensure the launch edition of Advanced Therapies Integrates becomes the leading event that facilitates the translation of cutting-edge research and disruptive innovation into the wide-spread adoption of Advanced Therapies, delivering improved patient outcomes and a revolution in healthcare economics.

We also have support from a number of other media and PR organisations. You can find out more below.

If you are a member of the press and would like to attend this event, please request a press pass by clicking on the image on the right of the page.

We welcome enquiries from other media partners who would like to work with us. If this is of interest please contact Jo Stickings.

 22 June 2021


7 October 2021


Over 300 attendees live on the day

The online digital event with real-time, face to face networking






senior industry

Our lead media partners are:



The Medicine Maker is a global publication that showcases the pharma industry’s success stories and examines its biggest points of contention. Engaging content covers the entire spectrum of drug development, keeping all medicine makers up to date with the most pressing topics, trends and technologies driving the drug development and manufacturing industry forward.

You can find out more about The Medicine Maker here.


The Cell + Gene Curator is a short, weekly newsletter connecting you to discoveries, process innovation, and business updates from the cell and gene therapy community. We trawl the news, speak with the right people, and dig for research gold to bring you the latest insight, analysis, and words of wisdom from the advanced therapies field.

Subscribe to The Cell + Gene Curator here.

Our other media partners

Click for more info

Life science insights

Do you want to share your news with our community? Our Social Media reach includes 6,700 followers on Twitter and 9,000 connections on LinkedIn. Send your news to to be included in our communications plan.

Nanoform technology delivers successful results for Herantis CDNF drug candidate

Nanoform technology delivers successful results for Herantis CDNF drug candidate

Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc (“Herantis”), focusing on disease modifying therapies for debilitating neurodegenerative diseases based on the natural body protein CDNF (Cerebral Dopamine Neurotrophic Factor), today announced that results from the Nanoform Proof of Concept (PoC) project show that the nanoforming process has been successfully applied to Herantis’ rhCDNF drug candidate.

read more

Sign up for life science integrates news

Get the latest news and updates by signing up today.

By signing up to the life science integrates newsletter, you have read and agree to our Privacy Policy, including our Cookie use.

People  |   Processes   |   Predictions

 LIVE ONLINE 7 October 2021